NINDS NOI 23-011941

Submitted by patelsnv on
Post Date/ Solicitation Issue Date
Closing Response Date
Proposed Award Date
Project Title
gpcrMAX panel
Contracting Office
National Institute of Neurological Disorders and Stroke (NINDS)

Contact Points

Primary Contract Specialist

ELAINE
ESTRELLA
elaine.estrella@nih.gov
NAICS Code Number
325413
In-Vitro Diagnostic Substance Manufacturing
Small Business Size Standard
1250
FPDS Classification Code
Q301
Estimated Period of Performance
08/07/2023 - 09/30/2023
Delivery of Goods
BLDG 35 RM 3A213
Set-Aside Status
Not Set Aside
Competition Status
Brand Name or Equal
Brand Name
EUROFINS
Rationale/ Salient Characteristics
This is the only source to obtain this service because the cell lines and technology are only available through this company. No other contractor can fulfill our requirements because we need to compare our data back to previously obtained data from the parent compound many years ago. Further, Eurofins DiscoverX conducts these highly specialized assays regularly. They are experienced in high throughput screens like screening our lead compounds at 168 different G protein-coupled receptors. As such, they are industry leading experts at this type of experiment making them qualified as well as the sole source. They will provide us with the results approximately 22 after running the assay.
Single-Sole Source Determination
contractor running the assay must performs high throughput screens - screens lead compound at 168 different G-protein coupled receptors and 3 weeks turnaround after running assay.
Background/Description of Requirement

Statement of Need and Purpose: We need to assess the global selectivity of our lead D3 dopamine receptor negative allosteric modulator candidates. Modifying the parent compound to improve certain pharmacological characteristics could potentially also decrease selectivity. We need to know if our new lead candidates are still extremely selective for the D3 dopamine receptor which would reduce potential off-target effects when using the compounds in vitro or in vivo.

Background Information and Objective:  We are developing a new D3R-selective negative allosteric modulator scaffold for use as an in vitro or in vivo probe, or as a potential clinical lead compound. To accomplish this, we have set out to design highly selective D3 dopamine receptor negative allosteric modulators that do not have off target activity at other closely related or unrelated GPCRs. We used this screen from Eurofins DiscoverX when we first began developing this chemical scaffold. Since then, we have optimized the compound into higher potency lead compounds. We need to screen our lead candidates for off-target activity to ensure that any modification to the drug did not alter its selectivity. We would like to have Eurofins DiscoverX run their gpcrMAX panel in agonist and antagonist modalities. They are the only source for this assay and will run 168 G protein-coupled receptors at one concentration in duplicate. This will provide us with information on the selectivity of our leads at a broad array of receptors and predict if there will be off-target side effects. We will use this data to compare back to the parent compound which was run in the gpcrMAX panel many years ago. To run this assay ourselves is prohibitively expensive due to the need to buy 168 cell lines and would require months of work.

Purchase Description: gpcrMAX panel, gpcrMAX GPCR Functional Panel, DiscoverX, Eurofins DiscoverX, 86-0115.

Interested parties may identify in writing their interest and capability in response to this requirement. Responses to this notice shall contain sufficient information to establish the interested parties’ bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.

All responses must be received by closing date and must reference the announcement. Responses may be submitted electronically to the attention of the contract specialist. Fax responses will not be accepted.

All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency.